Trial of Enhanced Neurostimulation for Anorexia
NCT05788042, Not applicable, Recruiting, The George Institute
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Trial of Enhanced Neurostimulation for Anorexia | ClinicalTrials.gov |
| NCT number | NCT05788042 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 70 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | The George Institute | ClinicalTrials.gov |
| Conditions | Anorexia Nervosa | ClinicalTrials.gov |
| Interventions | MagPro TMS device (ARTG: 204659), tDCS mini-CT Stimulator (Soterix, USA: ARTG: 284637) | ClinicalTrials.gov |
| First posted | 2023-03-28 | ClinicalTrials.gov |
| Last updated | 2025-09-12 | ClinicalTrials.gov |
Registered outcomes 27
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Effectiveness - Eating Disorder Examination Questionnaire (EDE Q) | Change from baseline at 8 weeks | Self-report instrument that measures eating disorder behaviors and attitudes. Eating Disorder Examination Questionnaire; 28-items; rating scale 0 - 6; Higher scores on the global scale and subscales indicate more problematic eating behaviours and attitudes. | ClinicalTrials.gov |
| Primary | Acceptability | 8 weeks | Number of completed sessions for active tDCS and active rTMS in the acute 8 week RCT period. | ClinicalTrials.gov |
| Secondary | Weight | Change from baseline at 4 weeks | Change in Body Mass Index. Weight status in AN is considered a key determinant of remission from illness. | ClinicalTrials.gov |
| Secondary | Weight | Change from baseline at 8 weeks | Change in Body Mass Index. Weight status in AN is considered a key determinant of remission from illness. | ClinicalTrials.gov |
| Secondary | Weight | Change from baseline at 20 weeks | Change in Body Mass Index. Weight status in AN is considered a key determinant of remission from illness. | ClinicalTrials.gov |
| Secondary | Mood - Montgomery Asberg Depression Rating Score (MADRS) | Change from baseline at 4 weeks | Depressive symptomology is a common psychiatric comorbidity of AN and both tDCS and rTMS significantly improve mood symptoms. 10-items; rating scale 0- 6; Higher score indicates more severe depression. | ClinicalTrials.gov |
| Secondary | Mood - Montgomery Asberg Depression Rating Score (MADRS) | Change from baseline at 8 weeks | Depressive symptomology is a common psychiatric comorbidity of AN and both tDCS and rTMS significantly improve mood symptoms. 10-items; rating scale 0- 6; Higher score indicates more severe depression. | ClinicalTrials.gov |
| Secondary | Mood - Montgomery Asberg Depression Rating Score (MADRS) | Change from baseline at 20 weeks | Depressive symptomology is a common psychiatric comorbidity of AN and both tDCS and rTMS significantly improve mood symptoms. 10-items; rating scale 0- 6; Higher score indicates more severe depression. | ClinicalTrials.gov |
| Secondary | Neurocognition - Trail Making Test parts A and B (TMT: attention and cognitive flexibility) | Change from baseline at 8 weeks | Deficits in set shifting has been found to be common in people with AN. | ClinicalTrials.gov |
| Secondary | Neurocognition - Trail Making Test parts A and B (TMT: attention and cognitive flexibility) | Change from baseline at 20 weeks | Deficits in set shifting has been found to be common in people with AN. | ClinicalTrials.gov |
| Secondary | Neurocognition - Embedded Figures Test (EFT: field dependence vs independence). | Change from baseline at 8 weeks | This task assesses central coherence, or the degree of focus on details in processing information. Poor central coherence is a potential etiologic or maintaining factor for people with eating disorders. | ClinicalTrials.gov |
| Secondary | Neurocognition - Embedded Figures Test (EFT: field dependence vs independence). | Change from baseline at 20 weeks | This task assesses central coherence, or the degree of focus on details in processing information. Poor central coherence is a potential etiologic or maintaining factor for people with eating disorders. | ClinicalTrials.gov |
| Secondary | Neurocognition - STROOP Colour Word Test (response inhibition). | Change from baseline at 8 weeks | The STROOP task assesses inhibitory control, which has been shown to be reduced in people with eating disorders. | ClinicalTrials.gov |
| Secondary | Neurocognition - STROOP Colour Word Test (response inhibition). | Change from baseline at 20 weeks | The STROOP task assesses inhibitory control, which has been shown to be reduced in people with eating disorders. | ClinicalTrials.gov |
| Secondary | Neurocognition - Wisconsin Card Sorting Test (WSCT: perseveration). | Change from baseline at 8 weeks | This task has been found to be sensitive to set shifting deficits in people with AN. | ClinicalTrials.gov |
| Secondary | Neurocognition - Wisconsin Card Sorting Test (WSCT: perseveration). | Change from baseline at 20 weeks | This task has been found to be sensitive to set shifting deficits in people with AN. | ClinicalTrials.gov |
| Secondary | Psychological Symptoms - Depression Anxiety and Stress Scale (DASS-21) | Change from baseline at 8 weeks | Self reported questionnaire designed to measure the severity of a range of symptoms common to both Depression and Anxiety. 21-items; rating scale 0- 3; Higher scores on subscales indicate more severe depression, anxiety and stress. | ClinicalTrials.gov |
| Secondary | Psychological Symptoms - Depression Anxiety and Stress Scale (DASS-21) | Change from baseline at 20 weeks | Self reported questionnaire designed to measure the severity of a range of symptoms common to both Depression and Anxiety. 21-items; rating scale 0- 3; Higher scores on subscales indicate more severe depression, anxiety and stress. | ClinicalTrials.gov |
| Secondary | Functioning - The Assessment of Quality of Life Instrument (AQoL-4D) | Change from baseline at 8 weeks | Measures quality of life for independent living, mental health, relationships, and senses. It as chosen as measures can be used for economic evaluation based on Quality Adjusted Life Years (QALYs). 12-items; scale 1-4; Higher score indicates lower health-related quality of life. | ClinicalTrials.gov |
| Secondary | Functioning - The Assessment of Quality of Life Instrument (AQoL-4D) | Change from baseline at 20 weeks | Measures quality of life for independent living, mental health, relationships, and senses. It as chosen as measures can be used for economic evaluation based on Quality Adjusted Life Years (QALYs). 12-items; scale 1-4; Higher score indicates lower health-related quality of life. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 36
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 444788 | BACKGROUND | PubMed |
| 9474057 | BACKGROUND | PubMed |
| 11026183 | BACKGROUND | PubMed |
| 12153817 | BACKGROUND | PubMed |
| 15664172 | BACKGROUND | PubMed |
| 15852321 | BACKGROUND | PubMed |
| 16476129 | BACKGROUND | PubMed |
| 16485268 | BACKGROUND | PubMed |
| 20443202 | BACKGROUND | PubMed |
| 20923600 | BACKGROUND | PubMed |
| 21727255 | BACKGROUND | PubMed |
| 23121779 | BACKGROUND | PubMed |
| 23729277 | BACKGROUND | PubMed |
| 23995026 | BACKGROUND | PubMed |
| 24999420 | BACKGROUND | PubMed |
| 25189181 | BACKGROUND | PubMed |
| 26537308 | BACKGROUND | PubMed |
| 26661289 | BACKGROUND | PubMed |
| 27109830 | BACKGROUND | PubMed |
| 27160468 | BACKGROUND | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 5
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Card Sorting Test (Berg) | Secondary outcome | ConductCognition |
| Hidden Shapes Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Trail Making Test A | Secondary outcome | ConductCognition |
| Trail Making Test B | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)